Expert Review of Clinical Pharmacology最新文献_第3页

Targeting HIF-2α: the role of belzutifan in clear cell renal carcinoma management. 靶向 HIF-2α：belzutifan 在透明细胞肾癌治疗中的作用。

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2025-01-01 Epub Date: 2024-12-13 DOI: 10.1080/17512433.2024.2436433

Alejandro Valdés, Gonzalo Pizarro, Jaime González-Montero, Carlos Rojas, Mauricio Burotto

{"title":"Targeting HIF-2α: the role of belzutifan in clear cell renal carcinoma management.","authors":"Alejandro Valdés, Gonzalo Pizarro, Jaime González-Montero, Carlos Rojas, Mauricio Burotto","doi":"10.1080/17512433.2024.2436433","DOIUrl":"10.1080/17512433.2024.2436433","url":null,"abstract":"Introduction: Belzutifan is a first-in-class hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor. It targets the von Hippel-Lindau protein (pVHL)-HIF-vascular endothelial growth factor (VEGF) pathway, which is crucial in cellular responses to hypoxia. By inhibiting HIF-2α, belzutifan disrupts the transcription of genes involved in tumor growth and angiogenesis.Areas covered: In this review, we describe the pVHL-HIF-VEGF pathway and how it led to the development of HIF inhibitors, including belzutifan. A search was conducted for trials involving Belzutifan, including phase I-III trials. We describe the relevant toxicity, with emphasis on hypoxia and anemia.Expert opinion: Belzutifan is a relatively safe drug, with manageable adverse events, including anemia and hypoxia as on-target toxicity. Ongoing trials are studying its benefit in overall survival for RCC in first-line treatment and its potential in other malignancies. The LITESPARK-005 trial reported the benefit of belzutifan in progression-free survival (PFS) compared to everolimus in later lines of treatment, with improvement in quality-of-life outcomes. Given its different mechanism of action to currently available treatments, belzutifan is expected to play a prominent role in the treatment of clear cell renal carcinoma and other cancers.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"17-27"},"PeriodicalIF":3.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142817662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Person-centeredness in medication management with people living with dementia. 以人为本的痴呆患者药物管理。

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2025-01-01 Epub Date: 2025-01-21 DOI: 10.1080/17512433.2024.2448837

Mouna Sawan, Brendan Mccormack, Danijela Gnjidic

引用次数: 0

FLOT vs CROSS in localized esophageal adenocarcinoma: what is the current best strategy? FLOT vs CROSS治疗局限性食管腺癌：目前的最佳策略是什么？

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2025-01-01 Epub Date: 2025-01-02 DOI: 10.1080/17512433.2024.2447779

Jane E Rogers, Michael Leung, Jaffer A Ajani

引用次数: 0

Closing the gaps in the access to quality-assured medicines for global health: The case for oxytocin for postpartum haemorrhage. 为全球卫生缩小在获得有质量保证的药品方面的差距：产后出血使用催产素的案例。

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2025-01-01 Epub Date: 2025-01-09 DOI: 10.1080/17512433.2024.2447775

C C Lee, Luther Gwaza, Karin Rombouts, Peter Hu, Rutendo Kuwana, Bart Remmerie, Chioma Ejekam, Kehinde Okunade, Pete Lambert

{"title":"Closing the gaps in the access to quality-assured medicines for global health: The case for oxytocin for postpartum haemorrhage.","authors":"C C Lee, Luther Gwaza, Karin Rombouts, Peter Hu, Rutendo Kuwana, Bart Remmerie, Chioma Ejekam, Kehinde Okunade, Pete Lambert","doi":"10.1080/17512433.2024.2447775","DOIUrl":"10.1080/17512433.2024.2447775","url":null,"abstract":"Introduction: Access to quality-assured medicines remains unequal between high-income and low-income countries. To bridge this gap, product development and supply in low- and middle-income countries (LMICs) should follow World Health Organization (WHO)'s policies and recommendations whilst aligning with international standards.Areas covered: We reviewed two cases on oxytocin access for postpartum hemorrhage (PPH), a condition that disproportionately affects mothers in low-income countries. The first case examines the challenges in ensuring quality-assured oxytocin injections in LMICs. International technical guidelines allow different storage conditions for oxytocin, which can cause confusion in countries with weak regulatory oversight. WHO and partners recommend a common storage and management of oxytocin to resolve this issue. The second case explores the design of clinical studies for inhaled oxytocin, a promising candidate for PPH aiming for rapid registration and inclusion in WHO's therapeutic recommendations. Aligning scientific, regulatory, and WHO policy requirements early in the development process can expedite access to new effective medicines in LMICs, and we described the potential clinical challenges in meeting this.Expert opinion: Robust partnerships between stakeholders, to streamline medicine development and regulatory approval, are essential to close access gaps and ultimately prevent unnecessary deaths due to PPH in LMICs.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"41-49"},"PeriodicalIF":3.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142946842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Risk of new onset diabetes mellitus with pitavastatin as compared to atorvastatin and rosuvastatin: a systematic review and meta-analysis. 匹伐他汀与阿托伐他汀和罗苏伐他汀相比的新发糖尿病风险：系统回顾和荟萃分析。

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2024-12-01 Epub Date: 2024-11-25 DOI: 10.1080/17512433.2024.2433603

Harmanjit Singh, Sangambir Kaur, Parul Kaushal, Jatin Sharma, Mandeep Singla

{"title":"Risk of new onset diabetes mellitus with pitavastatin as compared to atorvastatin and rosuvastatin: a systematic review and meta-analysis.","authors":"Harmanjit Singh, Sangambir Kaur, Parul Kaushal, Jatin Sharma, Mandeep Singla","doi":"10.1080/17512433.2024.2433603","DOIUrl":"10.1080/17512433.2024.2433603","url":null,"abstract":"Background: Statins are linked to the risk of new-onset diabetes mellitus (NODM). While atorvastatin and rosuvastatin are often associated with NODM, pitavastatin may carry a lower risk. This systematic review and meta-analysis (SRMA) evaluated the impact of pitavastatin on NODM compared to atorvastatin and rosuvastatin.Methods: We conducted a systematic literature search using PubMed, CENTRAL, EMBASE, and ClinicalTrials.gov. Two authors independently screened studies, assessed the risk of bias using Joanna Briggs Institute, Newcastle-Ottawa, and Scottish Intercollegiate Guidelines Network checklists, and extracted data. The analysis was performed using RevMan 5.4.1, and results were represented as risk ratios (RR) with 95% confidence intervals (CI) and heterogeneity was evaluated using the I2 statistic.Results: Of 517 records screened, 13 studies were included, comprising observational studies, and randomized controlled trials. Most of the studies showed pitavastatin to be associated with a lower or no risk of NODM. Meta-analysis revealed that pitavastatin had a lower risk of NODM compared to atorvastatin (RR = 0.86, 95% CI = 0.79-0.93, p = 0.0002) and rosuvastatin (RR = 0.77, 95% CI = 0.71-0.84, p < 0.00001).Conclusion: Pitavastatin poses a lower risk of NODM than other statins, making it a potentially safer option for patients requiring long-term statin therapy.Protocol registration: www.crd.york.ac.uk/prospero identifier is CRD42022371741.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"1173-1181"},"PeriodicalIF":3.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142715870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The need for inhaled phosphodiesterase inhibitors in chronic obstructive pulmonary disease. 慢性阻塞性肺疾病患者吸入磷酸二酯酶抑制剂的必要性

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2024-12-01 Epub Date: 2024-12-05 DOI: 10.1080/17512433.2024.2438187

Mario Cazzola, Luigino Calzetta, Paola Rogliani, Maria Gabriella Matera

{"title":"The need for inhaled phosphodiesterase inhibitors in chronic obstructive pulmonary disease.","authors":"Mario Cazzola, Luigino Calzetta, Paola Rogliani, Maria Gabriella Matera","doi":"10.1080/17512433.2024.2438187","DOIUrl":"10.1080/17512433.2024.2438187","url":null,"abstract":"Introduction: The therapeutic implications of phosphodiesterase (PDE) inhibitors have attracted interest because PDEs are regarded as an intracellular target to be exploited for therapeutic advancements in the treatment of COPD. At present, the only approved approach for the treatment of COPD with PDE inhibitors is the use of an oral PDE4 inhibitor. However, this treatment is not widely employed, primarily due to the narrow therapeutic index associated with oral PDE4 inhibitors, which significantly limits the tolerable dose. The inhalation route represents a viable alternative to the oral route for improving the therapeutic index of PDE4 inhibitors.Areas covered: The development of inhaled PDE4 inhibitors, with a focus on tanimilast and ensifentrine, the latter of which is a dual PDE3/PDE4 inhibitor.Expert opinion: The inhalation route offers several advantages regarding the delivery of PDE inhibitors for the management of COPD. Tanimilast and ensifentrine have been shown to improve lung function, reduce exacerbations and enhance quality of life in COPD patients. However, it has not yet been determined which type of COPD patient might benefit more from inhaled PDE4 inhibitors, and it remains unclear whether concomitant inhibition of PDE3 and PDE4 confers a significant benefit compared to blocking PDE4 alone in COPD.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"1149-1161"},"PeriodicalIF":3.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142767469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A scoping review of the clinical utility of adverse drug reaction causality analysis tools for use in the hospital setting. 药物不良反应因果关系分析工具在医院环境中的临床应用范围综述。

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2024-12-01 Epub Date: 2024-11-22 DOI: 10.1080/17512433.2024.2429677

Benjamin Deutscher, Keshia De Guzman, Adam La Caze, Nazanin Falconer

{"title":"A scoping review of the clinical utility of adverse drug reaction causality analysis tools for use in the hospital setting.","authors":"Benjamin Deutscher, Keshia De Guzman, Adam La Caze, Nazanin Falconer","doi":"10.1080/17512433.2024.2429677","DOIUrl":"10.1080/17512433.2024.2429677","url":null,"abstract":"Introduction: Identification and monitoring of adverse drug reactions (ADRs) and interventions to reduce ADRs are essential for patient safety in hospitals. Causality analysis (CA) is an approach that helps to determine a causal link between medication and patient harm (i.e. an ADR). While numerous CA tools exist, there is no gold standard.Areas covered: Five online databases were searched to identify studies that evaluated the potential clinical utility of CA tools for ADRs. CA tools were mapped against the Bradford Hill (BH) criteria and included if they adhered to the first seven criteria proposed by BH. Upon the database search, 550 studies were identified, with 41 studies being selected that looked at tools mapped to BH. Thirty-four different CA tools were identified in the included studies.Expert opinion: Naranjo and WHO-UMC were the most reported CA tools for studies examining inter-rater and intra-rater reliability. Naranjo commonly received a 'fair' agreement level while WHO-UMC received a 'substantial' agreement level between raters. Along with kappa statistics, time using the CA tool was also analyzed, with WHO-UMC being the most time-efficient. There does not appear to be one CA tool that can be applied universally to pharmacovigilance efforts in hospital in-patient settings.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"1127-1148"},"PeriodicalIF":3.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142617228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The search for blood biomarkers useful in treating atopic dermatitis patients. 对治疗特应性皮炎患者有用的血液生物标志物的研究。

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2024-12-01 Epub Date: 2024-12-16 DOI: 10.1080/17512433.2024.2438192

Kenji Izuhara, Satoshi Nunomura, Takeshi Nakahara, Daisuke Onozuka

{"title":"The search for blood biomarkers useful in treating atopic dermatitis patients.","authors":"Kenji Izuhara, Satoshi Nunomura, Takeshi Nakahara, Daisuke Onozuka","doi":"10.1080/17512433.2024.2438192","DOIUrl":"10.1080/17512433.2024.2438192","url":null,"abstract":"Introduction: Atopic dermatitis (AD) is diagnosed based on clinical signs and symptoms as well as on a clinical course lacking distinct laboratory or histological features; however, the recent appearance of molecularly targeted drugs against AD urges us to try to discover and develop biomarkers useful for treating AD patients.Areas covered: This article commenced with a targeted PubMed search using 'atopic dermatitis' and 'biomarker' as keywords. We combined the findings from the B-PAD study that we have recently published and summarized data, particularly those recently published.Expert opinion: Many cells and molecules are listed as potential biomarkers of AD, most of which are type 2 mediators. Among them, CCL17/TARC is now thought to be the most reliable biomarker of AD. During the B-PAD study, we recently found that three biomarkers - squamous cell carcinoma antigen 2 (SCCA2), CCL26/eotaxin-3, and lactose dehydrogenase (LDH) - are better able than CCL17/TARC to assess the clinical severity and disease activity of AD. Moreover, although several biomarkers showed good ability to monitor the efficacy of molecularly targeted drugs against AD. More studies on the discovery and development of biomarkers of AD are awaited to refine treatments for AD patients.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"1163-1172"},"PeriodicalIF":3.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142779629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Changing landscapes and increasing relevance of immunotherapy in localized MSI-H gastric adenocarcinoma. 局部MSI-H型胃腺癌免疫治疗前景的变化和相关性的提高。

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2024-12-01 Epub Date: 2024-12-10 DOI: 10.1080/17512433.2024.2438178

Jane E Rogers, Jaffer A Ajani

引用次数: 0

The use of oral GnRH antagonists to inhibit the LH surge in women undergoing ovarian stimulation for in vitro fertilization. 使用口服 GnRH 拮抗剂抑制体外受精卵巢刺激妇女的 LH 激增。

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2024-12-01 Epub Date: 2024-11-11 DOI: 10.1080/17512433.2024.2428342

Valentina Grisendi, Giovanni Grandi, Martina Capuzzo, Antonio La Marca

引用次数: 0